The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.

Guests

  • Marc Kaufman Reporter on the national desk of "The Washington Post"
  • Dr. Jerry Avorn Author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
  • Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
  • Dr. Sandra Kweder Deputy director of the FDA's Office of New Drugs

Related Links

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

Untangling The Lies Of Rep. George Santos

Thursday, Jan 19 2023Behind the lies of Congressman George Santos. Diane talks to the owner of the small weekly paper that first broke the story, and a Washington Post journalist who is following the money to see who financed Santos's political rise.